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Accessible Synthetic Probes for Staining Actin inside
Platelets and Megakaryocytes by Employing Lifeact
Peptide
Lucia Cardo,[a, b] Steve G. Thomas,[b] Alexandra Mazharian,[b] Zoe Pikramenou,[a]
Joshua Z. Rappoport,[c] Michael J. Hannon,*[a] and Stephen P. Watson*[b]
Introduction
Actin is one of the most abundant proteins in eukaryotes that
can exist as filamentous actin (F-actin) formed from ATP-medi-
ated polymerisation of monomeric actin (G-actin) and existing
in highly dynamic supramolecular organisations. It is one of
the major components of the cytoskeleton playing a key role
in cell morphogenesis, division and motility; it is regulated and
organised by several actin-binding and signalling proteins.[1]
Methods to visualise actin dynamics without interfering with
their complex activity are particularly important for cell biolo-
gists, and one major challenge is to achieve this by using live
cell microscopy.[2]
Current approaches to observe real-time F-actin dynamics
use the incorporation of fluorescently labelled G-actin during
F-actin polymerisation or employ labelled F-actin binding
domains (ABDs, usually deriving from actin binding proteins)
as fluorescent markers.[3] Among these, a 17-residue peptide
sequence, named Lifeact, from the yeast actin crosslinker
Abp140 has been identified as the shortest sequence to inter-
act with F-actin.[4] Lifeact is ideally suited as a probe as it has
low toxicity and interference with natural actin dynamics as
well as the ability to tag a large distribution of actin structures;
therefore there is great interest in Lifeact-based markers for
imaging actin. However, existing strategies employing Lifeact,
as well as other ABDs or labelled G-actin, require fusion with
fluorescent proteins (GFP, RFP, etc.) and insertion in cells with
genetic modifications or by microinjection techniques;[4b,5]
these procedures do not always guarantee a proper control of
the level of the probe in cells, thus affecting its efficiency, re-
producibility and toxicity;[6] more importantly, they are not
suitable for all cell types or accessible for all research laborato-
ries. Platelets are one significant example of primary cells that
cannot be transformed (they are anucleate) or efficiently mi-
croinjected (due to their small size, 1–3 mm diameter), there-
fore real-time actin dynamic studies are limited to platelets iso-
lated from transgenic mice expressing GFP–actin markers.[7]
Cell staining upon incubation with synthetic actin markers,
such as labelled phallotoxins or jasplakinolide and their deriva-
tives, are the most employed alternative tools for visualising
actin structures by fluorescent microscopy. Bright, high-resolu-
tions images can be achieved thanks to the wide range of fluo-
rophore–phallotoxin conjugates commercially available, but
these compounds are either toxic (in fact they have also been
investigated as potential cytotoxic drugs), cell impermeable or
interfere with actin polymerisation. Consequently their use is
typically limited to the study of fixed cells or only for specific
experiments in which known effects on actin polymerisation
can be taken into account.[8] Attempts to reduce the toxicity of
known synthetic actin-binding compounds by designing new
derivatives have often been limited by the complexity and
costs of syntheses; however, one fluorogenic and cell-permea-
Lifeact is a 17-residue peptide that can be employed in cell mi-
croscopy as a probe for F-actin when fused to fluorescent pro-
teins, but therefore is not suitable for all cell types. We have
conjugated fluorescently labelled Lifeact to three different cell-
penetrating systems (a myristoylated carrier (myr), the pH low
insertion peptide (pHLIP) and the cationic peptide TAT) as a
strategy to deliver Lifeact into cells and developed new tools
for actin staining with improved synthetic accessibility and low
toxicity, focusing on their suitability in platelets and megakar-
yocytes. Using confocal microscopy, we characterised the cell
distribution of the new hybrids in fixed cells, and found that
both myr– and pHLIP–Lifeact conjugates provide efficient actin
staining upon cleavage of Lifeact from the carriers, without
affecting cell spreading. This new approach could facilitate the
design of new tools for actin visualisation.
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ble actin marker with remarkably reduced toxicity has recently
been identified among several synthetic jasplakinolide deriva-
tives.[9] This is a promising tool, although its potential needs to
be characterised further as it shows different behaviours in dif-
ferent cell lines.
We aimed to develop alternative synthetic actin markers
with improved synthetic accessibility and reduced toxicity ;
these being the main limits of the few existing compounds.
We focus on the markers’ suitability for actin staining in
human platelets, as developing new approaches for these cells
would help to understand important events in thrombosis and
haemostasis; we also verify their versatility in megakaryocytes
(MKs), which are responsible for platelet production. Due to
the known actin affinity/low toxicity combination, fluorescently
labelled Lifeact should guarantee minimum interference with
actin dynamics (compared to other existing actin binders),
therefore it is an ideal component for an actin marker. Because
it is not cell permeable, we explore three different carriers able
to promote the delivery and release of labelled Lifeact into the
cytosol of platelets and MKs. To the best of our knowledge,
there is only one successful example of a membrane-permea-
ble synthetic carrier–Lifeact conjugate, which was designed ex-
clusively for live imaging in plant cells, in which Lifeact was
fused to the antimicrobial peptide BP100 as a specific vector
for these cells.[10]
We investigate three different systems as potential vectors
for Lifeact: a myristoylated (myr) carrier,[11] the pH low insertion
peptide (pHLIP)[12] and the cationic cell-penetrating peptide
(CPP) TAT.[13] We conjugated Life-
act to each of these carriers
both through disulfide-based
linkers and covalent bonds, and
investigated the efficiency of the
new hybrids as actin probes and
the cell distribution of the carri-
ers by fluorescent confocal mi-
croscopy with actin staining as
an unambiguous read out.
Results and Discussion
Design and synthesis
Platelets are small cells (1–3 mm)
that can be readily isolated from
blood and kept in buffer for up
to 6–8 h. In this study, we inves-
tigated three potential carriers
for Lifeact, selecting relatively
small ones among the large vari-
ety of cell-penetrating materials
available and known to promote
fast cell uptake of their cargos
(<30–60 min).[14] Also, they are
hypothesised to penetrate cell
membranes by different mecha-
nisms, thus we were able to in-
vestigate the compatibility of different delivery methods into
platelets. Lipid-based carriers, such as the myr system that we
employed here, are believed to be independent from mem-
brane-recognition events and are, therefore, more versatile
than peptide-based carriers.[11,15] Furthermore, both palmitoyla-
tion and myristoylation have been employed to deliver poten-
tial antiplatelet drugs, thus proving their compatibility with
platelets.[16] pHLIP is a 38-residue transmembrane peptide helix
isolated from bacteriorhodopsin C that is able to deliver sever-
al cargos (conjugated at the C terminus by a cleavable link) in
response to pH changes: at low pH (between 6.5 and 7.0),
pHLIP folds into an a-helix conformation able to penetrate the
cell membrane, translocate the cargo and release it upon cyto-
solic disulfide reduction. An increase in pH (between 7.0 and
7.5) unfolds the a-helix and releases the carrier to the extracel-
lular environment.[17] This carrier is also compatible with plate-
lets; we have recently described its ability to deliver nanomate-
rials into these cells.[18] Finally, we employed the TAT peptide,
which is one of the most common CPPs and widely employed
in drug-delivery research.
We conjugated Lifeact to each carrier through a disulfide-
bond-based linker to allow cleavage and release of the probe
in the reductive environment in the cytosol after membrane
penetration. We modified Lifeact at the C-terminal by adding
a Lys residue labelled with carboxyfluorescein (FAM) so as to
allow fluorescent detection of actin staining; at the N-terminal
we added a Cys residue for disulfide bond formation with the
carrier. Each of the three selected carriers was modified at the
Scheme 1. Synthesis of carrier–Lifeact hybrids. Scheme of conjugation between carriers (labelled with TAMRA) and
Lifeact (labelled with FAM) by disulfide bond exchange and a list of the cleavable (by disulfide reduction) and un-
cleavable compounds investigated for cell imaging.
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C-terminal by adding a Cys followed by a Lys residue labelled
with carboxytetramethylrhodamine (TAMRA) for fluorescent de-
tection of the carrier ; the thiol group of the Cys was protected
by a 2-thiopyridyl group to allow thiol–disulfide exchange with
the cargo Lifeact (Scheme 1). We prepared three cleavable
compounds: Myr-S-S-Life (5), pHLIP-S-S-Life (6) and TAT-S-S-Life
(7). To understand the role of cleavage in Lifeact delivery, we
also prepared three analogous uncleavable systems in which
carrier and Lifeact are covalently bound: Myr–Life (8), pHLIP–
Life (9) and TAT–Life (10).
The compounds were obtained by one-step conjugation be-
tween commercial peptides or by following standard and re-
liable synthetic procedures (peptide synthesis, amino group
labelling and disulfide exchange) ; this is one advantage com-
pared to other actin markers obtained by complex multistep
organic syntheses.
The FAM/TAMRA pair (donor and acceptor, respectively) is
suitable for FRET spectroscopy and this plays a dual function:
providing an additional tool to monitor cleavage and cell
uptake[19] and reducing the background fluorescence originat-
ing from extracellular or uncleaved Lifeact(FAM). Emission
scans of the cleavable compounds 5, 6 and 7 in the presence
of a reducing agent confirm that energy transfer occurs when
the disulfide bond is intact and that its cleavage causes a de-
crease in FRET and a large increase in donor emission intensity
(Figure S1).
Figure 1. Actin staining in human platelets. Washed platelets were treated with different probes and analysed by confocal fluorescence microscopy. A) Repre-
sentative actin staining of platelets with Alexa 488 Phalloidin upon fixation and permeabilisation (lex=488, stress 1: fibres, 2: lamellipodia and 3: filopodia).
B)–D) Cells treated with Lifeact(FAM) (1) only: B) and D) are fluorescence images at standard gain and upon gain increase, respectively; C) is the correspond-
ing reflection image showing correct platelets spreading. E), G) and I) Lifeact(FAM) detection (actin staining) in platelets preincubated with 5 (4 mm), 6 (4 mm)
and 7 (0.5 mm), respectively, spread on fibrinogen and fixed. F), H) and J) Corresponding carrier(TAMRA) detection (lex=543). Representative enlargements are
indicated with arrows; scale bars: 10 mm. See also Figures S2 and S3.
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Confocal microscopy in fixed platelets and megakaryocytes
We investigated the synthesised compounds’ efficiency as
actin probes by confocal microscopy in fixed human platelets,
aiming to achieve a level of actin staining that is comparable
with that observed for Alexa Fluor 488 Phalloidin. Figure 1A
shows phalloidin marking distinctive actin organisations in pla-
telets, such as stress fibres, lamellipodia and filopodia.
Suspensions of washed human platelets (2107 cellsmL1)
in Tyrode’s buffer were incubated with different carrier–Lifeact
systems (concentrations of incubation between 0.5 and 10 mm
were investigated), transferred onto cover slips for spreading
on fibrinogen and fixed. Detection of FAM and TAMRA emis-
sions by confocal microscopy allowed visualisation of actin
staining by Lifeact and the distribution of the carriers in cells,
respectively. The image in Figure 1B confirms that Lifeact(FAM)
(1) alone does not penetrate cells without an appropriate
carrier, as no actin staining or any other fluorescence was
observed, although platelets spreading was unaffected (Fig-
ure 1C). Only a large increase in both gain and laser power
allowed visualisation of weak fluorescence that could not be
recognised as actin filament staining (Figure 1D). Figure 1E–L
shows fluorescence images of platelets treated with 5 (4 mm, E
and F), 6 (4 mm, G and H) and 7 (0.5 mm, I and J). The emission
of Lifeact(FAM) and carrier(TAMRA) are on the left and right, re-
spectively, and representative enlargements are indicated. By
employing both Myr-S-S-Life and pHLIP-S-S-Life (Figure 1E and
G), we observed normal spreading of platelets and typical
staining of common F-actin structures (stress fibres, lamellipo-
dia and filopodia); this is comparable to the staining achieved
with phalloidin (Figure 1A). In both cases, carriers(TAMRA) (Fig-
ure 1F and H) are present inside cells, but clearly separate
from Lifeact(FAM) and not involved in actin staining, thus indi-
cating that cleavage between carriers and Lifeact had occurred
(additional images in Figures S2 and S3). In contrast, TAT-S-S-
Life significantly affects platelet viability; even at relatively low
concentrations (1–2 mm) of compound, more than 50% of cells
are incorrectly spread on fibrinogen (Figure S2O–R). At lower
concentrations (0.5–1 mm, necessary to observe emission), pla-
telets treated with this probe present a reduced mean surface
area compared to controls and to cells incubated with the
other two probes. In addition, both cleavage and actin staining
are uncertain as Lifeact(FAM) (Figure 1 I) and TAT(TAMRA) stain-
ing (Figures 1J and S2) appear to overlap.
The procedure employed for sample preparation is based on
preincubation of cells with the probes, thereby proving that
1) the new compounds do not need a permeabilisation step,
which is necessary for penetration of phalloidin, and 2) cell
spreading is not influenced by preincubation with the new sys-
tems. However, as a further control, we prepared slides accord-
ing to the same procedure employed for platelets stained with
phalloidin, in which spread cells were fixed, permeabilised and
treated with the carrier–Lifeact systems; no significant im-
provement in actin staining was observed (Figure S4). A range
of incubation times (0–45 min) was also explored; this showed
that images of platelets preincubated with the probe for
45 min prior spreading are brighter ; however, satisfactory
staining was also observed when using incubation times of a
few minutes (Figure S5), thus indicating fast uptake. We decid-
ed to keep incubation times of 30 min for all our experiments.
In order to characterise and compare Myr-S-S-Life and
pHLIP-S-S-Life, we quantified both florescence intensities and
areas of relevant regions of the cells. In particular, we observed
that both myr and pHLIP carriers accumulated in very distinct
regions of the cells, possibly in membrane-dense regions. We
selected and analysed these “carrier-dense” regions (black lines
in Figure 2A) using as threshold a ratio between mean TAMRA
intensities of carrier-dense areas and mean TAMRA intensities
of the corresponding entire cell above 1.5 (for each selected
cell). The chart in Figure 2B reports the percentage area of se-
lected carrier-dense regions relative to the cell area at different
concentrations of Myr-S-S-Life and pHLIP-S-S-Life. Generally,
“myr-dense” areas are 1.9 times larger than “pHLIP-dense”
areas at the lowest concentration of probe and 2.8 times at
the highest concentration, thus indicating that myristoylation
Figure 2. Analysis of probes. Platelets were treated with different concentra-
tions of 5 (&) and 6 (&) spread on fibrinogen, fixed and imaged by confocal
microscopy. Carrier-dense regions were selected in TAMRA emission images
(indicated with black lines in (A)) ; their mean area [% relative to the total
cell areaSEM] was measured in (B). From FAM emission images of the
same cells, the mean emission intensities (SEM) of Lifeact(FAM), which are
representative of actin staining, were measured in (C). Each bar is the aver-
age of at least 100 measured [area]/[mean intensity] from two different ex-
periments. See also Figures S6 and S7.
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introduces a higher concentration of carrier stack in cells. Fur-
thermore, the concentration of compound during incubation
affects myr-dense areas (threefold increase over the concentra-
tion range of 0.5 to 10 mm) more than pHLIP-dense areas (two-
fold increase over the same range). The higher accumulation
of myr in platelets could be simply the consequence of
a higher cell uptake of myr–Lifeact hybrid. Alternatively, the
different cell distribution observed is consistent with proposed
theories about the internalisation processes of these carriers.
Myristoylated carriers are believed to penetrate cells based on
their affinity for lipid cell membranes, and the concentration-
dependent accumulation that we observe in platelets suggests
that the vector remains anchored at the platelets’ membranes.
This is also in agreement with studies in which myristoylation
and palmitoylation were employed to enhance the activity of
anti-platelet drugs targeting receptors at the inner leaflet of
transmembrane proteins.[16c,20]
As a contrast, we incubated platelets with pHLIP-S-S-Life at
pH 6.5 to induce carrier penetration and cargo delivery, fol-
lowed by washes at pH 7.4 (controls confirmed that this does
not affect cell spreading), which should promote release of
membrane-attached carrier back to the extracellular environ-
ment.[12] This would explain why pHLIP accumulation is lower
than that of myr. We also observed significant delocalisation
between FAM and TAMRA emission signals in myr-dense re-
gions, whereas the two fluorophores partially colocalise in
pHLIP-dense regions (compare images in Figure 1E and F, and
G and H; more details are reported in Figures S2, S3 and S6);
this suggests that release of the cargo–Lifeact is more efficient
when employing myristoylation rather than pHLIP. This obser-
vation is important because detection of Lifeact(FAM) bound
to the carrier and not involved in actin staining might lead to
misinterpretation in actin studies; however, labelling the carrier
allowed uncleaved Lifeact to be identified in relatively small re-
gions (between 3 and 8% of total cell area); this did not influ-
ence the mean emission intensity of FAM (Figure S7). Measure-
ments of mean emission intensity of Lifeact(FAM) inside cells
(Figure 2C), associated with actin staining efficiency, indicate
that the brightness of the staining improves when the concen-
trations of both Myr-S-S-Life and pHLIP-S-S-Life are increased,
but higher emission intensities with lower concentrations of
probe are achieved with Myr-S-S-Life (additional controls in
Figure S7).
We treated human platelets with the uncleavable derivatives
Myr-Life (8 ; Figure 3A and B) and pHLIP-Life (9 ; Figure 3C and
D); no actin staining was observed in either case (0.5–10 mm
concentrations of compounds were explored), thus indicating
that release of Lifeact is essential for its binding with actin. Fur-
thermore, 8 affects platelet spreading even at 1 mm (Figure 3B).
A similar pattern of results was observed when platelets were
treated with carriers only: Myr(TAMRA) (2 ; Figure 3E and F) se-
verely affected cell spreading, although this could be a conse-
quence of carrier insolubility when it is not bound to a peptide,
although pHLIP(TAMRA) (3 ; Figure 3G and H) is randomly dis-
tributed in correctly spread cells. Images in Figure 3A and B re-
inforce the hypothesis that Myr remains anchored at the mem-
brane in such a way that its covalent link with the actin binder
affects cell viability. In contrast, the transmembrane fragment
pHLIP is unable to diffuse into the cytosol, as expected, but
the covalent binding with Lifeact does not interfere with cell
spreading, probably due to a different motility of the system in
membranes. We also observed that accumulation of both 9
and 3 (Figure 3C and G) is broad and random rather than con-
centrated in relatively small pHLIP-dense regions (as is that of
the cleavable pHLIP-S-S-Life); this suggests that the presence
of a cleavable cargo influences penetration and/or release of
the carrier.
Uncleavable TAT-Life (10) and carrier TAT(TAMRA) (4) were
also tested in platelets. Like the analogous cleavable system,
both compounds prevented cell spreading at low concentra-
Figure 3. Role of cleavage. Fluorescence images from confocal microscopy of platelets treated with A) uncleavable Myr-Life (8 ; 1 mm, lex=488 nm), C) pHLIP-
Life (9 ; 4 mm, lex=488 nm), E) carrier Myr(TAMRA) (2 ; 1 mm, lex=543 nm) and G) carrier pHLIP(TAMRA) (3 ; 4 mm, lex=543 nm). Corresponding reflection
images are shown in (B), (D), (F) and (H). Scale bars : 10 mm.
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tions, and staining by TAT-Life had no clear definition (Fig-
ure S8), thus confirming the incompatibility of the polycationic
TAT with platelets. The failure of a cell-penetrating system
could depend on a combination of factors (e.g. , the cargo–car-
rier–fluorophore combination, the type of linker, the type of
cell and its set of surface receptors). However, our images
show that all TAT-containing compounds affect platelet spread-
ing; this suggests that TAT is the disturbing component. There
are a few studies describing how polycationic-containing sys-
tems (including polylysine and TAT) influence both platelet ag-
gregation and activation, either by adhering to the negatively
charged platelet membranes and forming bridges between
adjacent cells or by interfering with specific membrane recep-
tors.[20,21] These might be related to the behaviour that we
observe, and this aspect should be taken into consideration
when planning cargo delivery in platelets employing polycat-
ionic carriers.
Since 5 and 6 are promising actin markers for platelets, we
tested their efficiency in megakaryocytes (MKs), which are re-
sponsible for platelet production. Figure 4A and B shows two
representative examples of MKs pretreated with 5 and 6, re-
spectively, spread on fibrinogen and fixed. Actin staining was
observed for compounds (Lifact(FAM) emission images on the
left), including marking of typical podosome structures (indi-
cated in the Figure 4A).[22] As observed in platelets, myristoylat-
ed carrier is densely accumulated in cells (carrier(TAMRA) emis-
sion images in the middle), whereas the emission of pHLIP is
significantly lower. Due to the highest complexity of actin fila-
ment organisation in these cells, colocalisation between carri-
ers and Lifeact is complex, and FRET microscopy is important
for interpretation: the images on the right were obtained by
detecting TAMRA emission caused by energy transfer upon ex-
citation of FAM at 488 nm; this occurs only if Lifeact is anch-
ored to the carrier. FRET intensity was higher than FAM emis-
sion intensity in cells treated with 5 (Figure 4A), thus indicat-
ing a large amount of uncleaved compound in cells. Instead,
only low FRET was detected in MKs treated with 6 (Figure 4B),
thus indicating low accumulation of uncleaved conjugate (see
analysis in Figure 4C).
In summary, we found that the known cell-penetrating
system TAT is not a suitable carrier for platelets, whereas both
Myr-S-S-Life (5) and pHLIP-S-S-Life (6) are efficient probes in
both fixed platelets and MKs, displaying F-actin staining prop-
erties that are comparable to those of phalloidin. A cytosolic
cleavable linker between the carrier and Lifeact is essential to
achieve actin staining, and incubation of the cells with the
probe (up to 10–20 mm) does not influence their correct
spreading on fibrinogen. In the case of myristoylation, cleav-
age from the cargo is also essential to avoid inhibition of cell
spreading. Both myr and pHLIP concentrate in carrier-dense re-
gions in platelets ; these are larger when myristoylation is em-
ployed (~15% of the cell area at 4 mm), although uncleaved
Lifeact was not observed. pHLIP-dense regions are significantly
reduced compared to myr-dense regions, and a low percent-
age of uncleaved Lifeact(FAM) was detected, although this did
not influence total Lifeact(FAM) emission intensity, related to
actin staining, in cells. pHLIP-S-S-Life is also able to deliver and
release Lifeact in MKs, whereas Myr-S-S-Life is not suitable for
these cells, due to the significant accumulation of uncleaved
compound, which would lead to misinterpretation of signals
from Lifeact(FAM). Further designs of analogous compounds
for MKs should consider inserting the cleavable bond in
a more extended linker to facilitate intracellular cleavage.
Real-time imaging in platelets.
Achieving real-time images of F-actin, especially in difficult and
important targets such as human platelets, is a critical chal-
lenge in cell microscopy. We performed live imaging experi-
ments with 5 and 6, but the results were not satisfactory. Al-
though reflection images display correctly spreading cells and
compound was detected in cell areas, delocalisation between
carriers and Lifeact was not observed, and actin staining com-
Figure 4. Actin staining in MKs. MKs were incubated with 5 mm of A) 5 or
B) 6 spread on fibrinogen, fixed and analysed by confocal fluorescence mi-
croscopy. Lifeact(FAM), carrier(TAMRA) and FRET images are on the left,
middle and right, respectively. Scale bars: 5 mm. A typical podosome struc-
ture is indicated with a white arrow in (A). C) Mean emission intensities
(SEM) of Lifeact(FAM), carrier(TAMRA) and FRET with 5 (&) and 6 (&) ; 20
cells from two different experiments were used for each measurement.
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parable to that observed in mice platelets by Lifeact-GFP[7] was
not achieved (Figures 5 and S9).
To verify whether cleavage of compound occurs in the pres-
ence of live cells, we measured FRET changes in 5 in the pres-
ence of platelets by fluorescence scans (Figure 6). In the con-
trol experiment in Tyrode’s buffer and in the absence of plate-
lets, upon excitation at 488 nm, the uncleaved compound
presents a stable emission profile (monitored for 20 min) with
two bands corresponding to FAM (the donor) and TAMRA (the
acceptor) at 520 and 580 nm, respectively, as a consequence of
energy transfer. Adding increasing concentrations of platelets
to a solution of Myr-S-S-Life (1 mm) in Tyrode’s buffer, induces
an increase in FAM emission and a decrease in TAMRA emis-
sion, with the anticorrelation that is typical for FRET decrease
(Figure 6A and B). In a parallel experiment (Figure 6C), we
prepared separate suspensions of human platelets (2
107 cellsmL1) in Tyrode’s buffer with different concentrations
of Myr-S-S-Life: at lower concentration of probe, we only ob-
served FAM emission, thus indicating that most of the com-
pound in solution is cleaved and confirming that platelets
cleave the disulfide bond. At the highest concentration, we
observed both FAM and TAMRA emission; this must indicate
extracellular excess of compound. These experiments demon-
strate rapid cleavage of compound in the presence of living
platelets (changes in emission were detected immediately after
additions) and inside cells, as a reductive environment is nec-
essary for disulfide bond rupture.
Nevertheless, despite the images of fixed cells above and
the fact that cleavage occurs as planned in platelets, live cell
images remain unsatisfactory. Due to a combination of factors,
images of actin in live transgenic mouse platelets labelled with
Lifeact-GFP are not nearly as clear as in fixed cell samples:[7]
the kinetics of the actin assembling/disassembling process, the
reversible nature of the actin–Lifeact interaction, background
issues particularly influential in such small cells and the physi-
cal-chemical properties of the fluorophore are all key compo-
nents affecting the quality of images of F-actin in living plate-
lets. Although we do not expect comparable quality between
live- and fixed-cell images, these synthetic Lifeact vectors do
not give staining that is comparable to Lifeact–GFP, and a few
explanations are possible.
The delivery process might not be complete or adequate,
and a fixation step might be necessary to promote access to
the actin. However, if this were the case, we might expect fixa-
tion to have the same beneficial effect on uncleavable Myr-Life
or Lifeact only, which it does not. Moreover, the live-cell experi-
ments in Figure 6 clearly indicate that cytosolic release of Life-
act(FAM) occurs and that it is complete when suspensions of
platelets (2107 cellsmL1) are treated with concentrations of
hybrids <1 mm.
Alternatively the Lifeact–FAM combination might not be the
most appropriate marker in terms of affinity for F-actin: the po-
sition and/or the nature of the fluorophore and/or the linker
between the fluorophore and Lifeact might affect the interac-
tion with F-actin resulting in poor visualisation of dynamic
events in real time. For example, Lukinavicius et al. identified
one efficient actin marker for live-cell imaging among a library
Figure 5. Representative real-time images of human platelets with 6. A) FAM
emission, B) TAMRA emission and C) reflection images by confocal microsco-
py. Scale bars : 10 mm. Platelets spread correctly on fibrinogen (C) but deloc-
alisation between carrier and Lifeact is not evident, thus probe release or
Lifeact(FAM) affinity with actin is uncertain. An example real-time image of
platelets treated with 5 in given in Figure S9.
Figure 6. Cleavage of Myr-S-S-Life (5) in the presence of living platelets.
A) Emission scans and B) maximum emission intensities of 5 in the presence
of increasing concentrations [cellsmL1] of human platelets in Tyrode’s
buffer. C) Emission scans of platelets (2107 cellsmL1) in the presence of
increasing concentrations of 5. The scan indicated with a dashed orange
line is 0.3 mm 5 without cells.
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of many derivatives, and modifications to the linker between
the fluorophore and the actin binder were key determinants of
activity.[9b] An et al. used pHLIP to deliver phalloidin into cancer
cells as an antiproliferative drug and observed that the pres-
ence of fluorophore on both carrier and cargo strongly influ-
enced the efficiency of the antiproliferative activity.[23] Finally,
the plant-cell-specific cell-penetrating carrier–Lifeact hybrid de-
scribed by Eggenberger et al.[10] highlights the importance of
the position of the fluorophore/carrier relative to the Lifeact
sequence and suggests that involving the C terminus of Lifeact
in the conjugation might affect the binding affinity with actin.
Thus, these myr- and pHLIP–Lifeact conjugates are suitable
as scaffolds for further elaboration and optimisation that might
enable live- as well as fixed-cell imaging. However, future
design aiming to enhance the affinity of the probe for F-actin
must be undertaken with caution, as this might also affect the
kinetics of actin assembly/disassembly, and the measurement
of “biological” real time, which is the ultimate goal.
Conclusions
There is a great interest in developing new methods to visual-
ise F-actin dynamics by cell microscopy, especially because cur-
rent methods cannot be applied to all cell types or rely on the
use of synthetic markers that are toxic or difficult to modify.
We have designed new systems for actin staining with im-
proved synthetic accessibility by employing the 17-residue se-
quence Lifeact as the actin-binding component so as to ensure
low interference with actin filaments and improve toxicity. We
conjugated Lifeact to three different cell-penetrating carriers
and investigated their ability to promote the delivery and re-
lease of Lifeact, and consequently actin staining, in difficult tar-
gets such as human platelets and megakaryocytes. We found
that the cationic carrier TAT is not suitable for these cells,
whereas both a myristoylated carrier and pHLIP, a pH-respon-
sive peptidic vector, promote Lifeact insertion without affect-
ing cell spreading. Actin staining, comparable with that of
commercially available phalloidin was observed in fluorescent
images of fixed cells upon cytosolic release of the cargo–Life-
act. We highlight the importance of both carrier and cargo la-
belling, possibly with a pair of fluorophores able to provide a
cleavage-responsive signal such as FRET, as tools to achieve a
better understanding of our hybrids.
Our studies confirm that bringing together delivery vectors,
cleavage sites and labelled Lifeact by employing fast and ver-
satile synthetic procedures, provide a “plug and play” accessi-
ble strategy useful for simplifying the design of new actin
markers with customisable physical, chemical and biological
features. This valuable approach might facilitate the screening
and identification of systems suitable for real-time images,
bearing in mind that the binding affinity of potential probes
with actin filaments, which is necessary for satisfactory visuali-
sation of dynamic events, must not affect their kinetics.
Experimental Section
Experimental procedures and instruments employed are detailed
in the Supporting Information. Here we briefly describe principal
methods employed.
Synthesis : The following peptides were purchased from Peptide
Protein Research Ltd. (Fareham, UK): Lifeact (1), pHLIP(TAMRA) (3)
and TAT(TAMRA) (4) were supplied with certified purity >80% and
employed for the following disulfide-exchange steps without fur-
ther purification; the uncleavable systems Myr-Life (8), pHLIP-Life
(9) and TAT-Life (10) were supplied with certified purity >98% and
employed for cell microscopy studies without further purification.
Both FAM and TAMRA were conjugated at the a-amino group of
the C-terminal lysine residue.
Myr (TAMRA) (2) was synthesised by Fmoc solid-phase synthesis
followed by Cys protection with thiopyridyl group and Lys labelling
with TAMRA. All cleavable compounds Myr-S-S-Life (5), pHLIP-S-S-
Life (6) and TAT-S-S-Life (7) were obtained by mixing 1 equiv of car-
rier 2, 3 and 4, respectively, with 2 equiv of 1 in DMF at room tem-
perature for 4 h. All reactions were monitored by analytical RP-
HPLC (0–100% CH3CN/0.05%TFA in H2O/0.05% TFA over 40 min),
the compounds were purified by semipreparative RP-HPLC (using
the same gradient) and characterised by mass spectrometry. All
the peptides were prepared in 150 mm solutions in Tyrode’s buffer
(134.0 mm NaCl, 2.90 mm KCl, 0.34 mm Na2HPO4·12H2O, 12.0 mm
NaHCO3, 20.0 mm HEPES, 1.0 mm MgCl2, pH 7.3). Concentrations
were checked by comparing the UV/Vis bands of the dyes, and ali-
quots were kept at 20 8C until their use for cell biology studies.
Cell microscopy. Suspensions of washed platelets (300 mL, 2
107 cellsmL1) were preincubated with different volumes of probe
solutions (150 mm, 0.5–10 mm concentration of probe during incu-
bation was the range explored) in Tyrode’s buffer containing glu-
cose (5 mm, pH 7.4) at 37 8C for 30 min. Suspensions were trans-
ferred onto glass coverslips precoated with fibrinogen and allowed
to spread at 37 8C for 45 min. For pHLIP–Lifeact systems, incuba-
tion and spreading were in Tyrode’s buffer containing glucose
(5 mm) at pH 6.5. Spread cells were washed with phosphate-buf-
fered saline (PBS), fixed with 10% formalin, treated with NH4Cl2
(50 mm), washed again with PBS and mounted on slides for mi-
croscopy. The same procedure was employed to stain MKs, except
that cell suspensions of 5108 cellsmL1 were employed for incu-
bation and spreading was allowed in medium (and not buffer) for
3 h prior to fixation and mounting. For control platelets stained
with phalloidin, platelet suspension (2107 cellsmL1 in Tyrode’s
buffer) was allowed to spread on glass coverslips precoated with fi-
brinogen for 45 min at 37 8C, fixed with formalin, permeabilised
with 0.1% Triton X-100 in PBS and stained with Alexa Fluor 488
Phalloidin (15 nm) for 30 min at room temperature. Stained cells
were washed with PBS and deionised water and mounted on
slides for microscopy.
To allow proper comparison between different compounds, the
same microscope parameters (PMT, enlargement, laser power)
were employed in all the experiments (unless indicated differently).
Samples were imaged by using the 488 (Ar/ArKr laser), 543 and
633 nm (He/Ne laser) laser lines on a Leica DMIRE 2 laser scanning
confocal microscope with 63 , 1.4 N/A oil objective. Single images
were collected by selecting the best optical plane (i.e. , the one
that looked most in focus) and using averaging (3 scan accumula-
tions) to improve S/N. Post-imaging analyses (cell selections, mean
area and mean fluorescence intensity calculations) were performed
by using ImageJ 1.48.
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Accessible Synthetic Probes for
Staining Actin inside Platelets and
Megakaryocytes by Employing Lifeact
Peptide
Actin for the best: We have developed
fluorescent probes for F-actin in plate-
lets and megakaryocytes by conjugating
the actin-binding peptide, Lifeact, to
cell-permeable vectors by using a cyto-
solic cleavable linker. The synthetic ver-
satility and accessibility as well as reten-
tion of cell viability make advances in
actin-probe design.
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